Actos Bladder Cancer
In June 2011, the Food and Drug Administration warned that patients taking the diabetes drug Actos for more than one year may face an increased risk of developing bladder cancer. Multiple studies have linked the use of Actos to an increased bladder cancer risk, especially when the drug is taken over extended periods or at higher doses.
Concerns about the link between Actos and bladder cancer first arose in October 2005, when a study published in The Lancet revealed that Actos users displayed higher rates of bladder cancer than patients taking other diabetes medications. The FDA added a bladder cancer warning to Actos’ label in response to the study’s findings.
In March 2011, the European Medicines Agency began an investigation of Actos after receiving multiple reports of bladder cancer diagnoses from patients taking the drug. Researchers found that Actos users were more likely to develop bladder cancer than non-users, and that this risk increased significantly when patients were prescribed higher doses of the drug or took Actos for more than one year.
After researchers confirmed that Actos could increase a patient’s risk of developing bladder cancer, health officials in France and Germany suspended the use of Actos in those countries. The FDA also issued an Actos bladder cancer warning in response to these findings.
Patients who were prescribed the diabetes drug and have been diagnosed with bladder cancer have filed Actos lawsuits against its manufacturer. In spite of these lawsuits and the FDA’s warnings about the drug, the agency has not announced plans to issue an Actos recall.
If you or a loved one used Actos and were diagnosed with bladder cancer, you may be eligible to file a lawsuit and receive compensation. For a free legal consultation, contact the lawyers at Hissey Kientz, LLP by calling us toll-free at 1-866-275-4454, or by filling out the free case evaluation form located on the right side of this page.